Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified ...

According to Benzinga Pro, Bristol-Myers Squibb's peer group average for short interest as a percentage of float is 3.41%, which means the company has less short interest than most of its peers. Did ...

On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings ...

Changes in sleep metrics detected with wearable technology could serve as an inflammation marker and potentially predict IBD ...

The Subject Expert Committee (SEC) under the Cardiovascular division of the Central Drugs Standard Control Organisation (CDSCO) has approved the protocol amendment submitted ...

Dispatch Biotherapeutics Inc. is taking aim at solid tumors with a new viral vector/antigen technology backed by major industry names such as Arch Venture Partners and Bristol Myers Squibb Co. With ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

Shares of Bristol Myers Squibb Co. BMY advanced 2.00% to $48.98 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.78% to ...

Discover how targeted therapies are revolutionizing autoimmune disease treatment by offering greater precision.

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...